Skip to main
  1. Stocks
  2. Silence Therapeutics
  3. Forecast
SLN

Silence Therapeutics (SLN) Stock Forecast & Price Target

Silence Therapeutics (SLN) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Silence Therapeutics is attractive because divesiran has strong biological and clinical validation in polycythemia vera, with Phase 2 SANRECO data showing an 87.5% response rate versus 18.8% on placebo and Phase 1 durability including a median 287 days to first phlebotomy after the final dose. The Merck acquisition further validates the mRNAi GOLD platform, while the company’s roughly $300 million market cap appears modest relative to a 75% probability of success, especially given the dosing advantage of Q6W or Q12W versus weekly competitors and a potential benchmark from rusfertide’s $1 billion to $2.3 billion NPV. Its wholly owned pipeline in cardiovascular disease, hematology, and rare disease adds additional optionality, but the near-term thesis is most tightly anchored to divesiran’s ability to reduce phlebotomy burden, improve hematocrit control, and support a registrational path.

Bears say

Silence Therapeutics is facing a weakened investment case because the Lp(a)HORIZON Phase 3 miss removed the key external catalyst for zerlasiran and, in management’s own framing, shifted the story largely onto divesiran. The company then suffered a major valuation reset as zerlasiran was assigned 0% probability of success versus 60% prior, while the model also assumes $200 million annual capital raises from 2028E to 2031E, implying dilution and a total firm value of about $1.2 billion versus $4.5 billion previously. In addition, divesiran remains commercially and clinically challenged in a crowded PV market, where sapablursen is already ahead in Phase 3 and the downside case suggests the stock could trade near cash if efficacy disappoints.

Silence Therapeutics (SLN) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Silence Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Silence Therapeutics (SLN) Analyst Forecast & Price Prediction

Get the latest Silence Therapeutics (SLN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Silence Therapeutics (SLN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Silence Therapeutics (SLN) Forecast

Analysts have given Silence Therapeutics (SLN) a Hold based on their latest research and market trends.

According to 2 analysts, Silence Therapeutics (SLN) has a Hold consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Silence Therapeutics (SLN)


Silence Therapeutics (SLN) Analyst Forecast & Price Prediction

Get the latest Silence Therapeutics (SLN) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Silence Therapeutics (SLN)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SLN stock data and trends